We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock
DCPH

Delisted

DCPH was delisted on the 10th of June, 2024.

Back to rankings

49 hedge funds and large institutions have $275M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
49
Holders Change
+49
Holders Change %
–
% of All Funds
1.22%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
49
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NLVP
New Leaf Venture Partners
New York
+$75.2M
2
Viking Global Investors
Viking Global Investors
Connecticut
+$45.6M
3
SHI
SV Health Investors
Massachusetts
+$31.4M
4
RG
Redmile Group
California
+$13.2M
5
Millennium Management
Millennium Management
New York
+$12.6M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Norges Bank
26
Norges Bank
Norway
$1.42M +$1.37M +75,000 New
SFM
27
Sphera Funds Management
Israel
$1.42M +$1.37M +75,000 New
PVI
28
Pura Vida Investments
New York
$1.33M +$1.28M +70,000 New
GTC
29
Ghost Tree Capital
New York
$1.22M +$1.18M +64,410 New
Victory Capital Management
30
Victory Capital Management
Texas
$1.14M +$1.1M +60,000 New
HI
31
HBK Investments
Texas
$1.04M +$1.01M +55,000 New
Tudor Investment Corp
32
Tudor Investment Corp
Connecticut
$999K +$964K +52,630 New
HCMT
33
Highland Capital Management (Texas)
Texas
$997K +$962K +52,500 New
SSA
34
Schonfeld Strategic Advisors
New York
$950K +$916K +50,000 New
EC
35
EcoR1 Capital
California
$855K +$824K +45,000 New
HHC
36
Hutchin Hill Capital
New York
$530K +$511K +27,915 New
MWNA
37
Marshall Wace North America
New York
$519K +$501K +27,337 New
IBT
38
International Biotechnology Trust
United Kingdom
$478K +$458K +25,000 New
Barclays
39
Barclays
United Kingdom
$475K +$458K +25,000 New
DCM
40
DAFNA Capital Management
California
$380K +$366K +20,000 New
Wellington Management Group
41
Wellington Management Group
Massachusetts
$267K +$257K +14,044 New
LCM
42
Landscape Capital Management
New Jersey
$201K +$194K +10,600 New
QCMA
43
Quad Capital Management Advisors
New York
$190K +$183K +10,000 New
BlackRock
44
BlackRock
New York
$169K +$163K +8,888 New
FMA
45
FNY Managed Accounts
New York
$153K +$148K +8,100 New
SG Americas Securities
46
SG Americas Securities
New York
$143K +$138K +7,544 New
PCM
47
Prelude Capital Management
New York
$31K +$29.6K +1,613 New
Wells Fargo
48
Wells Fargo
California
$28K +$27.5K +1,500 New
Credit Agricole
49
Credit Agricole
France
$19K +$18.3K +1,000 New
CCA
50
Catalyst Capital Advisors
New York
$6K +$5.59K +305 New
1
2

DCPH Hedge Fund Activity: Q3 2017 in Review

49 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2017, worth a combined $275M.

Buyers outnumbered sellers: 49 funds opened new DCPH positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was New Leaf Venture Partners, opening a new position worth an estimated $75.2M.

  • 49 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2017, up from 0 in Q2 2017.
  • Funds reported $275M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2017.
  • 49 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 0 closed out, a net change of +49 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was New Leaf Venture Partners, an estimated $75.2M added.

Based on aggregated 13F filings for Q3 2017.